Summary
The provided content does not contain an AI-generated claim to compare against the FDA label; therefore label-absence/coverage cannot be verified and the audit cannot be confirmed as on-label.
Category Scores
Accurate Statements
INTUNIV is indicated for treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications (Section 1).
INDICATIONS AND USAGE (1): “INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications”.
INTUNIV administration instructions include swallowing tablets whole and not crushing/chewing/breaking; also do not administer with high-fat meals (Section 2.1).
General Instruction for Use (2.1): “Swallow tablets whole. Do not crush, chew, or break tablets…” and “Do not administer with high fat meals…”.
INTUNIV can cause dose-dependent decreases in blood pressure and heart rate (Section 5.1).
Hypotension, Bradycardia, and Syncope (5.1): “Treatment with INTUNIV can cause dose-dependent decreases in blood pressure and heart rate.”
Abrupt discontinuation can result in rebound hypertension; tapering guidance of no more than 1 mg every 3 to 7 days is provided (Section 5.4).
Rebound Hypertension (5.4): “abrupt discontinuation… has resulted in… rebound hypertension…” and “tapered in decrements of no more than 1 mg every 3 to 7 days”.
Unsupported Statements
The AI response claim: “absent from the label.”
No specific AI-generated medical claim text is provided to assess; the audit includes an assertion of absence without mapping to an identifiable claim and without demonstrating label search/coverage for that claim.
“overall_audit_result”: inconclusive and “adheres_to_FDA_approved_labeling”: cannot be determined.
These statements are not grounded in an evaluable single claim/label comparison; they reflect missing inputs rather than verifiable on-label alignment or misalignment.
Contradictions
Important Omissions
The exact AI-generated claim(s) that are purportedly “absent from the label,” including the exact wording and any cited label sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because the key claim text is missing, the audit cannot verify whether the AI output omitted, misstated, or misrepresented critical label safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No specific AI claim was provided for label-absence/coverage verification; therefore the audit result cannot be substantiated.
Suggested Improvement
Provide the exact AI-generated claim(s) to evaluate (verbatim) and the portions of the label to which the AI claim allegedly corresponds; then re-run the alignment check section-by-section (indication, dosing/administration, contraindications, warnings/precautions including boxed warnings, interactions, and relevant populations).